Amryt Pharma (AMYT) to Acquire Chiasma (CHMA) in all-stock deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/15/2024
- Futures gain after lower-than-expected rise in inflation
- BMO raises S&P 500 price target to 5600
- Consumer price growth slowed marginally in March; CPI rose an annualized 3.4%
- S&P 500 rally not expected to accelerate from current levels: JPMorgan
- Dell stock gains as Morgan Stanley ups target on AI business momentum
- AMC Entertainment (AMC) Halted on Circuit Breaker, Up 121%
- Andy Jassy makes AWS leadership announcement (AMZN), says Matt Garman will become CEO of AWS
- BMO Capital Reiterates Underperform Rating on Plug Power (PLUG)
- Faraday Future Intelligent Electric (FFIE) Issues Statement on Recent Social Media Post
- Alibaba (BABA) stock tumbles after earnings fall short
- AMC Entertainment, Boot Barn, Boeing fall premarket; Nextracker rises
- After-hours movers: AMC Entertainment, DLocal, Boot Barn, and more
- Midday movers: GameStop, AMC Entertainment rise; Alibaba falls
- After-hours movers: AMC Entertainment, StoneCo, Fulcrum Therapeutics, and more
- Midday movers: Intel, Arm, Apple, GameStop rise; Alphabet falls
Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
May 5, 2021 7:00 AM EDT- Combined business will have three approved commercial products, lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myalepta®), octreotide (MYCAPSSA®) and a robust clinical pipeline
- Lead pipeline product Oleogel-S10*(Filsuvez®) under regulatory review in the US and EU
- Deal expected to pave a path to a combined potential $1BN peak revenue for Amryt
- The acquisition is expected to deliver estimated annual cost synergies of approximately $50M and be revenue and EBITDA accretive and cash generative in the first full calendar year of combined operations and substantially... More
